RxDoctor Payments Data

Henry Goodwin, MD

Urology · Evans, GANPI 1265467286

Payments from drug & device makers

$9,744in general payments, 2019–2025

Across 309 payments — averaging $31.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myriad Genetic Laboratories, Inc.$849
  • Axonics, Inc.$747
  • Johnson & Johnson$700
  • Astellas Pharma US Inc$698
  • AbbVie$578
  • Bayer$537
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$9,46497%
  • Education$2803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,744 in reported general payments places this provider in the 70th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$552,803
Medicare patients
1,299
Services billed
10,836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide56$836,630
XtandiEnzalutamide56$822,103
OrgovyxRelugolix174$461,358
NubeqaDarolutamide24$320,206
MyrbetriqMirabegron175$152,060
GemtesaVibegron75$47,591
Tamsulosin Hcl872$11,355
Potassium Citrate ErPotassium Citrate86$10,103
Finasteride514$7,640
Estradiol96$7,002
Silodosin38$3,912
Testosterone20$3,700
Trospium Chloride53$2,706
Alfuzosin Hcl ErAlfuzosin Hcl102$2,525
Testosterone Cypionate51$1,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$698$974,163231 claims
Johnson & JohnsonErleada$700$836,63056 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$463$508,949249 claims
BayerNubeqa$537$320,20624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 369 urology providers in Georgia.

Other urology in Evans

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →